Filing Flows

Filing Flows › Companies › GE HealthCare Technologies › Cash flow

GE HealthCare Technologies cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$793M in Q3 2026

Operating cash flow$907M
Capital spending−$114M
Free cash flow+$793M
Cash / net income1.5×

Analysis

In Q3 2026, GE HealthCare Technologies generated $907M of operating cash flow and spent $114M on capital projects, leaving free cash flow of $793M. That is $310M more than in Q3 2025 ($483M).

Operating cash flow was $907M against net income of $623M — 1.5× profit, cash ran ahead of reported earnings. The largest differences: employee-related liabilities +$187M, depreciation & amortization +$163M, inventory −$120M.

Free cash flow

GE HealthCare Technologies: free cash flow by quarterGE HealthCare Technologies: free cash flow by quarter$811MQ4 2024$98.0MQ1 2025$8.0MQ2 2025$483MQ3 2025$916MQ4 2025$112MQ1 2026$68.0MQ2 2026$793MQ3 2026
Operating cash flow less capital spending.
GE HealthCare Technologies: operating cash flow against capital spendingGE HealthCare Technologies: operating cash flow against capital spendingOperating cash flowCapital spending$913M$102MQ4 2024$250M$152MQ1 2025$94.0M$86.0MQ2 2025$593M$110MQ3 2025$1.1B$134MQ4 2025$290M$178MQ1 2026$168M$100MQ2 2026$907M$114MQ3 2026
Latest (Q3 2026): Operating cash flow $907M, Capital spending $114M.

Capital allocation, year by year

GE HealthCare Technologies: where the cash came from (up) and went (down), by fiscal yearGE HealthCare Technologies: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow $1.6BFY2021: Net borrowing −$12.0MFY2021: Asset sales $15.0MFY2021: Capital spending −$248MFY2021: Acquisitions −$1.5B$1.6BFY2021FY2022: Operating cash flow $2.1BFY2022: Net borrowing $8.2BFY2022: Asset sales $4.0MFY2022: Capital spending −$310M$10.3BFY2022FY2023: Operating cash flow $2.1BFY2023: Net borrowing $1.1BFY2023: Shares issued $34.0MFY2023: Asset sales $1.0MFY2023: Capital spending −$387MFY2023: Acquisitions −$147MFY2023: Dividends −$41.0M$3.3BFY2023FY2024: Operating cash flow $2.0BFY2024: Net borrowing −$423MFY2024: Shares issued $33.0MFY2024: Capital spending −$401MFY2024: Acquisitions −$313MFY2024: Dividends −$55.0M$2.0BFY2024FY2025: Operating cash flow $2.0BFY2025: Net borrowing $968MFY2025: Shares issued $37.0MFY2025: Capital spending −$482MFY2025: Acquisitions −$378MFY2025: Buybacks −$200MFY2025: Dividends −$64.0M$3.0BFY2025
Over these 5 years operating cash flow totalled $9.8B; the largest uses were acquisitions ($2.3B) and capital spending ($1.8B). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.8B
Debt$10.0B
Net debt$7.2B
Due within a year$508M

GE HealthCare Technologies funds itself: free cash flow was — over the last twelve months, and $2.8B of cash and investments stands against $10.0B of debt ($508M due within a year, 5.6× covered by cash).

GE HealthCare Technologies: debt maturities by year (FY2025)GE HealthCare Technologies: debt maturities by year (FY2025)$508MYear 1$1.8BYear 2$600MYear 3$1.0BYear 4$1.2BYear 5$4.9BAfter year 5
Principal due in each year as disclosed in the annual report, against $2.8B of cash and investments now.

Where the cash came from and went

GE HealthCare Technologies: sources (+) and uses (−) of cash, Q3 2026GE HealthCare Technologies: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$907MCash drawn (+) / kept (−)−$749MCapital spending−$114MDividends−$16.0MTaxes on employees’ shares−$15.0MOther financing−$9.0MExchange rates−$7.0MOther investing$3.0MShares issued$2.0MNet borrowing (+) / repaid (−)−$2.0M

From profit to cash

GE HealthCare Technologies: net income to operating cash flow, Q3 2026GE HealthCare Technologies: net income to operating cash flow, Q3 2026Net income$623MDepreciation & amortization$163MStock-based pay$36.0MGains on investments$6.0MGains on disposals−$2.0MReceivables−$59.0MInventory−$120MPayables$61.0MEmployee-related liabilities$187MDeferred revenue$47.0MOperating cash flow$907M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksDividendsNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$907M−$114M——−$16.0M−$2.0M$2.0M−$749M$793M
Q2 2026$168M−$100M$4.0M−$200M−$16.0M−$9.0M—$180M$68.0M
Q1 2026$290M−$178M−$2.3B−$100M−$16.0M$148M$10.0M$2.2B$112M
Q4 2025$1.1B−$134M−$99.0M—−$16.0M−$262M$12.0M−$486M$916M
Q3 2025$593M−$110M—−$100M−$16.0M−$4.0M$4.0M−$264M$483M
Q2 2025$94.0M−$86.0M−$10.0M−$100M−$16.0M$1.5B$1.0M−$1.3B$8.0M
Q1 2025$250M−$152M−$269M—−$16.0M−$256M$20.0M$416M$98.0M
Q4 2024$913M−$102M−$54.0M—−$14.0M−$1.3B$2.0M$679M$811M

GE HealthCare Technologies: income statement and cash flow

GE HealthCare Technologies, Q3 2026: revenue $5.5B (+7% year over year), operating margin 14.6%. The chart follows the revenue to costs, profit and cash.

GE HealthCare Technologies: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.